Abstract
As the first targeted systemic agent for the treatment of moderate to severe atopic dermatitis (AD), dupilumab represents a novel therapeutic opportunity for both patients and providers. However, a subset of patients receiving dupilumab are either partial responders who exhibit some improvement in Investigator’s Global Assessment score but not sufficient to meet the primary endpoint, or are non-durable responders who achieve therapeutic endpoint with subsequent partial loss of efficacy. We propose a therapeutic algorithm for the management of dupilumab partial responders and non-durable responders that involves maximizing topical therapy, seeking alternative diagnoses, and using dupilumab in conjunction with traditional systemic immunosuppressive agents. With a number of targeted agents for AD in the drug development pipeline, we encourage patients who do not have an adequate response to dupilumab to remain patient and optimistic as the arsenal of AD treatment modalities continues to expand.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 565-569 |
| Number of pages | 5 |
| Journal | American Journal of Clinical Dermatology |
| Volume | 20 |
| Issue number | 4 |
| DOIs | |
| State | Published - Aug 1 2019 |
Funding
Vivian Shi is a stock shareholder of Dermveda, has served as an advisor for Sanofi Genzyme/Regeneron, AbbVie, Novartis, SUN Pharma, Pfizer, Menlo Therapeutics, Burt’s Bees, GpSkin, the National Eczema Association and Global Parents for Eczema Research, is an investigator for AbbVie, Regeneron, Novartis, and LEO Pharma, and has received research funding from the Foundation for Atopic Dermatitis and Skin Actives Scientific. There were no incentives or transactions financial or otherwise relevant to this manuscript. Peter Lio has served as an investigator, speaker, advisory board member, and consultant for Sanofi Genzyme/Regeneron. There were no incentives or transactions financial or otherwise relevant to this manuscript. Aleksi Hendricks has no potential conflicts of interest to declare.
ASJC Scopus subject areas
- Dermatology
